Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H19NO2 |
| Molecular Weight | 197.2741 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)C[C@@]1(CN)C[C@@H]2CC[C@@H]2C1
InChI
InChIKey=ASBDKEXHKWHAPE-JZYVYDRUSA-N
InChI=1S/C11H19NO2/c1-14-10(13)6-11(7-12)4-8-2-3-9(8)5-11/h8-9H,2-7,12H2,1H3/t8-,9+,11+
PD-217014 or PD-217,014, a new GABA analog was developed by Pfizer as a potent alpha(2)delta ligand of voltage-gated calcium channel, that and possessed visceral analgesic activity. This compound was undergoing phase II clinical trials for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). In addition, PD-217014 was investigated for postherpetic neuralgia treatment. However, all these studies were discontinued.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000041533
Created by
admin on Mon Mar 31 21:08:21 GMT 2025 , Edited by admin on Mon Mar 31 21:08:21 GMT 2025
|
PRIMARY | |||
|
DTXSID801030092
Created by
admin on Mon Mar 31 21:08:21 GMT 2025 , Edited by admin on Mon Mar 31 21:08:21 GMT 2025
|
PRIMARY | |||
|
444088-20-4
Created by
admin on Mon Mar 31 21:08:21 GMT 2025 , Edited by admin on Mon Mar 31 21:08:21 GMT 2025
|
PRIMARY | |||
|
K2T93E812G
Created by
admin on Mon Mar 31 21:08:21 GMT 2025 , Edited by admin on Mon Mar 31 21:08:21 GMT 2025
|
PRIMARY | |||
|
PD-217,014
Created by
admin on Mon Mar 31 21:08:21 GMT 2025 , Edited by admin on Mon Mar 31 21:08:21 GMT 2025
|
PRIMARY | |||
|
DB12493
Created by
admin on Mon Mar 31 21:08:21 GMT 2025 , Edited by admin on Mon Mar 31 21:08:21 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
